	HOME
	WHAT IS ULCERATIVE COLITIS?
	ABOUT APRISO
	WORKING WITH YOUR DOCTOR
»	LIVING WITH UC HOW TO LIVE WITH UC
	SIGN UP FOR UC INFORMATION
	SIGN UP FOR APRISO SAVINGS

PRESCRIBING INFORMATION

FOR HEALTHCARE PROFESSIONALS

Living with UC

Bringing great ideas to life.

With ulcerative colitis (UC), months can go by without symptoms. These stretches of time are known as remission. During these times some people may like to think they don't have UC anymore. But then symptoms return, and this is called a flare.

To your doctor, a flare-up is when the lining of your colon becomes inflamed. To you, it may be painful, disruptive or even embarrassing. Symptoms include bleeding, diarrhea, cramping and fatigue.

Some people may "tough it out" or tell themselves things aren't really that bad. They may be used to excusing themselves from business meetings or family gatherings, or canceling plans altogether. Some simple steps and the right medication can change all that.

We've got several useful tips and tools that can help you plan carefully enough to do the things you really want to do. With a little preparation, you can get back to your life.

APRISO is a locally acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older. APRISO is contraindicated in patients with hypersensitivity to salicylates or aminosalicylates (sulfasalazine) or to any of the components of APRISO capsules. It is recommended that patients have an evaluation of renal function prior to initiation of APRISO therapy and periodically while on therapy. Exercise caution when using APRISO in patients with known renal dysfunction or a history of renal disease. There have been reports of hepatic failure in patients with pre–existing liver disease who have been administered mesalamine. Caution should be exercised when administering APRISO to patients with liver disease. The recommended dose of APRISO is four 0.375–g capsules once daily in the morning (1.5 g/day) with or without food. Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be coadministered with antacids. Patients with phenylketonuria should be aware that APRISO contains aspartame, equivalent to 2.24 mg of phenylalanine per day. In 2 well–controlled clinical trials, the most common treatment–related adverse events occurring in at least 3% of adult patients taking 1.5 g/day of APRISO were headache (11% vs 8% for placebo), diarrhea (8% vs 7% for placebo), upper abdominal pain (5% vs 3% for placebo), nausea (4% vs 3% for placebo), nasopharyngitis (4% vs 3% for placebo), influenza and influenza–like illness (4% vs 4% for placebo), and sinusitis (3% vs 3% for placebo).

For complete Prescribing Information, please click here.